l-663536 and Psoriasis

l-663536 has been researched along with Psoriasis* in 2 studies

Reviews

1 review(s) available for l-663536 and Psoriasis

ArticleYear
Leukotriene antagonists and inhibitors: clinical applications.
    Advances in prostaglandin, thromboxane, and leukotriene research, 1995, Volume: 23

    Topics: Animals; Asthma; Glomerulonephritis; Humans; Hydroxyurea; Indoles; Inflammatory Bowel Diseases; Leukotriene Antagonists; Leukotrienes; Membrane Proteins; Propionates; Psoriasis; Quinolines; Receptors, Leukotriene

1995

Trials

1 trial(s) available for l-663536 and Psoriasis

ArticleYear
Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK886) in psoriasis.
    Skin pharmacology : the official journal of the Skin Pharmacology Society, 1991, Volume: 4, Issue:4

    Antipsoriatic agents have been shown to decrease skin levels of arachidonic acid and its metabolites including 12-monohydroxy-eicosatetranoic acid (12-HETE), and leukotriene B4 (LTB4). In addition, specific systemic and topical lipoxygenase inhibitors have been reported to be effective in the treatment of psoriasis. The objective of this study was to investigate the effect of a potent oral leukotriene biosynthesis inhibitor (MK886) in patients with chronic plaque psoriasis. Clinical response together with the changes of LTB4 levels in lesional skin biopsy specimens, and urinary leukotriene E4 (LTE4) excretion were evaluated. In addition, markers of inflammation, proliferation and keratinization were studied immunohistochemically. No change in clinical scores or lesional LTB4 levels were observed with a 10 1/3-day course of MK886. A statistically significant reduction in urinary LTE4 excretion was observed: mean LTE4 (ng/h) were 5.14 before treatment and 1.51 on day 11 with MK886; and 7.55 before treatment and 6.57 on day 11 with placebo treatment. Epidermal accumulation of polymorphonuclear leukocytes (PMN) tended to diminish in the MK886 treatment group. These results indicate that although a reduction (greater than 70%) in urinary LTE4 excretion was found, and a slight decrease of epidermal PMN accumulation was observed, no correlative changes in clinical scores or LTB4 levels in skin lesion were found with a short course of MK886.

    Topics: Administration, Oral; Adult; Aged; Biomarkers; Biopsy; Dermatitis; Double-Blind Method; Female; Humans; Immunohistochemistry; Indoles; Keratins; Leukotriene Antagonists; Leukotriene B4; Male; Middle Aged; Psoriasis; Skin

1991